DMPI - DelMar Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3662
+0.0064 (+1.78%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.3598
Open0.3700
Bid0.3620 x 1100
Ask0.3662 x 4000
Day's Range0.3111 - 0.3719
52 Week Range0.2810 - 1.0500
Volume372,916
Avg. Volume272,896
Market Cap9.369M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-0.3980
Earnings DateMay 15, 2019 - May 21, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
    PR Newswire15 days ago

    DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board

    VANCOUVER, British Columbia and MENLO PARK, Calif., April 4, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the formation of a Scientific Advisory Board (SAB). Its inaugural members are Drs. Napoleone Ferrara and John de Groot.  Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, is an expert in glioma biology and angiogenesis, which is the key area of clinical development for VAL-083, the Company's lead asset.

  • DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083
    PR Newswire16 days ago

    DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083

    VANCOUVER, British Columbia and MENLO PARK, Calif., April 3, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the University of Texas MD Anderson Cancer Center's (MDACC) Institutional Review Board (IRB) has approved a trial protocol amendment to expand DelMar's ongoing Phase 2 clinical trial of VAL-083 in patients with MGMT-unmethylated glioblastoma (GBM). The biomarker driven trial, which was originally designed as a single arm study evaluating VAL-083 in patients with MGMT-unmethylated bevacizumab (Avastin)-naïve recurrent GBM, has been expanded to include an additional maintenance-stage (adjuvant therapy) treatment group.

  • DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
    PR Newswire2 months ago

    DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

    VANCOUVER, British Columbia and MENLO PARK, Calif., Feb. 20, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme (GBM) has achieved its halfway enrollment point. This trial, targeted to enroll up to thirty patients, is a single-arm, open-label study testing VAL-083 in combination with standard radiotherapy in GBM patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene.  An estimated 60% of GBM patients possess an unmethylated MGMT gene, which confers a more limited response to current standard of care treatment as well as a lower survival probability.

  • ACCESSWIRE2 months ago

    DelMar Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 19, 2019 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on February 19, 2019 ...

  • DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results
    PR Newswire2 months ago

    DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results

    - Company will host a business update conference call on February 19, 2019 at 4:30 PM Eastern Time - VANCOUVER, British Columbia and MENLO PARK, Calif. , Feb. 12, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, ...

  • DelMar Pharmaceuticals Receives Nasdaq Listing Extension
    PR Newswire2 months ago

    DelMar Pharmaceuticals Receives Nasdaq Listing Extension

    VANCOUVER, British Columbia and MENLO PARK, Calif. , Feb. 7, 2019 /PRNewswire/ --  DelMar Pharmaceuticals, Inc.  (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company ...

  • GlobeNewswire5 months ago

    Consolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic, The Ultimate Software Group, Internet Gold Golden Lines, and DelMar Pharmaceuticals — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting
    PR Newswire5 months ago

    DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

    VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 20, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, presented scientific updates, including data from two ongoing clinical trials, at the 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) held on November 15-18, 2018 in New Orleans, LA. "In our much-awaited Phase 2 study of VAL-083 in patients with MGMT-unmethylated, Bevacizumab-Naïve Recurrent Glioblastoma Multiforme (rGBM), we are pleased with the accelerated enrollment of this study with the vast majority of subjects already enrolled. The preclinical and clinical efficacy of VAL-083 in MGMT-unmethylated GBM population, along with the 2017 revised NCCN guidelines for MGMT-unmethylated patients which cautions against the use of temozolomide for MGMT-unmethylated GBM patients, creates a therapeutic opportunity not only for newly diagnosed patients, but also in the follow-on maintenance setting currently using temozolomide, all of which signals a path forward for VAL-083," added Mr. Zarrabian.

  • DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results
    PR Newswire5 months ago

    DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results

    - Company will host a business update conference call on November 20, 2018 at 4:30 PM Eastern Time - VANCOUVER, British Columbia and MENLO PARK, Calif. , Nov. 14, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, ...

  • InvestorPlace6 months ago

    Treat Aurora Cannabis Stock Normally at Your Own Peril

    In retrospect, it looks like Aurora Cannabis (NYSE:ACB) is following in the same unfortunate steps as DelMar Pharmaceuticals (NASDAQ:DMPI), Therapix Biosciences (NASDAQ:TRPX) and Maxar Technologies (NYSE:MAXR). Although ACB stock has only been a NYSE-listed ticker since Tuesday, it’s already down 18% since Monday’s last trade as an OTC-listed ticker, and is still pointed lower. ACB stock was already in a downtrend that technically started back on Oct. 16.

  • Simply Wall St.6 months ago

    Who Owns Most Of DelMar Pharmaceuticals Inc (NASDAQ:DMPI)?

    A look at the shareholders of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders Read More...

  • DelMar Announces Further Validation of the Mechanism of Action of VAL-083
    PR Newswire6 months ago

    DelMar Announces Further Validation of the Mechanism of Action of VAL-083

    VANCOUVER, British Columbia and MENLO PARK, Calif. , Oct. 10, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, Inc.  (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company ...

  • DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results
    PR Newswire7 months ago

    DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results

    - Company will host a business update conference call on September 25, 2018 at 4:30 PM Eastern Time - VANCOUVER, British Columbia and MENLO PARK, Calif. , Sept. 24, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, ...

  • DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor
    PR Newswire7 months ago

    DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor

    VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 4, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the appointment of Oppenheimer & Co. Inc. to serve as its strategic advisor. In this capacity, the firm will work on behalf of DelMar to manage the exploration and evaluation of a wide range of strategic opportunities with the goal of facilitating shareholder value generation. While the Company is evaluating strategic opportunities, there can be no assurance that this strategic review will result in a transaction.

  • DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM
    PR Newswire10 months ago

    DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM

    VANCOUVER, British Columbia and MENLO PARK, Calif. , June 26, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company ...

  • DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
    PR Newswire10 months ago

    DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors

    VANCOUVER, British Columbia and MENLO PARK, Calif., June 25, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the appointment of Napoleone Ferrara, M.D., to its Board of Directors. Dr. Ferrara is a world-renowned molecular biologist in the field of angiogenesis. Most notably, Dr. Ferrara is credited with the discovery of vascular endothelial growth factor (VEGF) and the first anti-VEGF antibody which suppresses the growth of a variety of tumors.

  • ACCESSWIRE11 months ago

    Wired News – Keryx Biopharmaceuticals Shares Results of Clinical Trial for Treating Patients with Advanced Chronic Kidney Disease with Ferric Citrate

    LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Keryx Biopharma, Inc. (NASDAQ: KERX) ("Keryx"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KERX as the Company's latest news hit the wire. On May 25, 2018, the Company shared the data from an investigator sponsored clinical trial that showed the impact of the use of ferric citrate in treating patients with advanced chronic kidney disease (CKD). The Company presented the results at the recently-held 55th ERA-EDTA Congress held at Copenhagen, Denmark, from May 24, 2018, to May 27, 2018.

  • DelMar Appoints Saiid Zarrabian to Full-Time President and CEO
    PR Newswire11 months ago

    DelMar Appoints Saiid Zarrabian to Full-Time President and CEO

    VANCOUVER, British Columbia and MENLO PARK, Calif., May 22, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (the "Company")(DMPI) today announced that the board of directors (the "Board") has appointed Saiid Zarrabian as the full-time President and Chief Executive Officer of the Company, effective immediately. Mr. Zarrabian had previously served as the Company's interim President and Chief Executive Officer since November 2017 and prior to that as an independent board member since July 2017.

  • DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results
    PR Newswire11 months ago

    DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results

    - Company will host a business update conference call on May 30, 2018 at 4:30 PM Eastern Time - VANCOUVER, British Columbia and MENLO PARK, Calif. , May, 17, 2018 /PRNewswire/ --  DelMar Pharmaceuticals, ...